Skip to main content

Free Content Adoption of the new antimalarial drug policy in Tanzania – a cross-sectional study in the community

Download Article:

You have access to the full text article on a website external to Ingenta Connect.

Please click here to view this article on Wiley Online Library.

You may be required to register and activate access on Wiley Online Library before you can obtain the full text. If you have any queries please visit Wiley Online Library


Summary Objective 

To assess the diffusion of the change of first line antimalarial drug from chloroquine (CQ) to sulphadoxine/pyrimethamine (SP) at household level in a rural district of Tanzania less than a year after the policy implementation. Methods 

Caretakers in 729 households were interviewed on knowledge of the new policy, home stocking of antimalarials, home-treatment practices of children younger than 5 years with fever, health-seeking behaviour and experience of SP. SP and CQ levels in blood were analysed from 328 children younger than 5 years in the households. Twelve focus group discussions (FGD) were performed with mothers, fathers and health workers. Results 

About 51% of the population knew that SP was the first line antimalarial. Only 8% of mothers stocked antimalarials, and only 4% stated self-treatment as the first action. We estimated that 84% of the children who had had fever during the last 4 weeks sought care at public health facilities. SP was detectable in 18% of the total child population and in 32% of those with reported fever, CQ in only 5% and 7%, respectively. The FGDs revealed negative perceptions of SP and fear of severe adverse reactions with mass media reported as key informant. Conclusion 

The policy had diffused to the communities in the sense that CQ had been changed to SP, which was well known as first line treatment. Moreover, there was a reported dramatic change from self-treatment with CQ to seeking care at public health facilities where SP was given under observation.

Keywords: Tanzania; artemisinin-based combination therapy; chloroquine; policy change; policy cycle; sulphadoxine/pyrimethamine

Document Type: Research Article


Affiliations: 1: Department of Clinical Pharmacology, Muhimbili University College of Health Sciences (MUCHS), Dar-es-Salaam, Tanzania 2: Department of Clinical Pharmacology, MUCHS, Dar-es-Salaam, Tanzania 3: Department of Sociology, University of Dar-es-Salaam, Dar-es-Salaam, Tanzania 4: Nordic School of Public Health, Gothenburg, Sweden and Division of International Health (IHCAR), Department of Public Health Sciences, Karolinska Institutet, Stockholm, Sweden 5: Division of Clinical Pharmacology, Department of Laboratory Medicine, Huddinge University Hospital, Karolinska Institutet, Stockholm, Sweden 6: Division of International Health (IHCAR), Department of Public Health Sciences, Karolinska Institutet, Stockholm, Sweden

Publication date: October 1, 2005

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Partial Open Access Content
Partial Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more